Marc F Botteman

Summary

Affiliation: Abt Associates
Country: USA

Publications

  1. ncbi request reprint The burden and outcomes associated with four leukemias: AML, ALL, CLL and CML
    Alberto Redaelli
    Pharmacia Corporation, Milan, Italy
    Expert Rev Anticancer Ther 3:311-29. 2003
  2. ncbi request reprint The health economics of bladder cancer: a comprehensive review of the published literature
    Marc F Botteman
    Abt Associates Inc, Bethesda, Maryland 20814, USA
    Pharmacoeconomics 21:1315-30. 2003
  3. doi request reprint Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling
    Rahul D Ballal
    Georgetown University, Washington, DC, USA
    Curr Med Res Opin 24:753-68. 2008
  4. ncbi request reprint Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United
    Marc F Botteman
    International Health Economics, HERQuLES, Abt Associates Clinical Trials, Bethesda, Maryland 20814, USA
    Clin Ther 24:1960-86; discussion 1938. 2002
  5. ncbi request reprint Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder
    Sonya J Snedecor
    Pharmerit North America LLC, 4350 East West Highway, Suite 430, Bethesda, MD 20814, USA
    J Ment Health Policy Econ 13:27-35. 2010
  6. doi request reprint Clinical, economic and humanistic burdens of skeletal-related events associated with bone metastases
    John A Carter
    Pharmerit International, Bethesda, MD 20814, USA
    Expert Rev Pharmacoecon Outcomes Res 13:483-96. 2013
  7. doi request reprint Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis
    Sonya J Snedecor
    Pharmerit International, Bethesda, MD, USA
    J Med Econ 16:19-29. 2013
  8. doi request reprint Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours
    John A Carter
    Health Economics, Pharmerit International, Bethesda, MD 20814, USA
    Pharmacoeconomics 30:373-86. 2012
  9. pmc Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia
    Sonya J Snedecor
    Pharmerit North America, Bethesda, MD 20814, USA
    Sleep 32:817-24. 2009
  10. doi request reprint Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer
    Sonya J Snedecor
    Pharmerit North America LLC, Bethesda, MD 20814, USA
    Clin Ther 34:1334-49. 2012

Collaborators

Detail Information

Publications34

  1. ncbi request reprint The burden and outcomes associated with four leukemias: AML, ALL, CLL and CML
    Alberto Redaelli
    Pharmacia Corporation, Milan, Italy
    Expert Rev Anticancer Ther 3:311-29. 2003
    ....
  2. ncbi request reprint The health economics of bladder cancer: a comprehensive review of the published literature
    Marc F Botteman
    Abt Associates Inc, Bethesda, Maryland 20814, USA
    Pharmacoeconomics 21:1315-30. 2003
    ....
  3. doi request reprint Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling
    Rahul D Ballal
    Georgetown University, Washington, DC, USA
    Curr Med Res Opin 24:753-68. 2008
    ....
  4. ncbi request reprint Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United
    Marc F Botteman
    International Health Economics, HERQuLES, Abt Associates Clinical Trials, Bethesda, Maryland 20814, USA
    Clin Ther 24:1960-86; discussion 1938. 2002
    ..The long-term clinical course after DVT can be further complicated by excess mortality, recurrent venous thromboembolism (VTE), and the post-thrombotic syndrome (PTS), which may produce sizable long-term economic burdens...
  5. ncbi request reprint Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder
    Sonya J Snedecor
    Pharmerit North America LLC, 4350 East West Highway, Suite 430, Bethesda, MD 20814, USA
    J Ment Health Policy Econ 13:27-35. 2010
    ..Both conditions impose significant economic burden, with the US societal cost of depression estimated at USD 50 billion annually...
  6. doi request reprint Clinical, economic and humanistic burdens of skeletal-related events associated with bone metastases
    John A Carter
    Pharmerit International, Bethesda, MD 20814, USA
    Expert Rev Pharmacoecon Outcomes Res 13:483-96. 2013
    ..In this review of the clinical, economic and humanistic SRE burden, it was found that SRE types can be differentiated by these outcomes, although economic outcomes are far more frequently reported than clinical or humanistic. ..
  7. doi request reprint Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis
    Sonya J Snedecor
    Pharmerit International, Bethesda, MD, USA
    J Med Econ 16:19-29. 2013
    ..This analysis assessed the cost-effectiveness of denosumab vs zoledronic acid in bone-metastatic prostate cancer from a US payer perspective...
  8. doi request reprint Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours
    John A Carter
    Health Economics, Pharmerit International, Bethesda, MD 20814, USA
    Pharmacoeconomics 30:373-86. 2012
    ..Meanwhile, research should be conducted to improve our understanding of the impact on quality of life and medical costs of preventing SREs...
  9. pmc Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia
    Sonya J Snedecor
    Pharmerit North America, Bethesda, MD 20814, USA
    Sleep 32:817-24. 2009
    ..To assess the cost-effectiveness of treatment with eszopiclone for chronic primary insomnia in adults...
  10. doi request reprint Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer
    Sonya J Snedecor
    Pharmerit North America LLC, Bethesda, MD 20814, USA
    Clin Ther 34:1334-49. 2012
    ..81-1.11; P = 0.49) and disease progression (HR = 1.00; 95% CI, 0.89-1.11; P = 0.93) did not differ significantly between groups. Denosumab was associated with a nonsignificant reduction in serious adverse events (44.4% vs 46.5%)...
  11. doi request reprint Estimating preference-based EQ-5D health state utilities or item responses from neuropathic pain scores
    Ning Yan Gu
    Pharmerit International, Bethesda, MD 20814, USA
    Patient 5:185-97. 2012
    ..When the direct evidence of such is lacking and only condition-specific scores are available, establishing a 'mapping' relationship between instruments can be useful...
  12. ncbi request reprint A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia
    Kimbach T Carpiuc
    Pharmerit North America LLC, 7272 Wisconsin Avenue, Suite 300, Bethesda, Maryland 20814, USA
    Expert Opin Pharmacother 8:2775-87. 2007
    ....
  13. pmc Eliciting health state utilities for Dupuytren's contracture using a discrete choice experiment
    Ning Yan Gu
    Pharmerit International, Bethesda, MD, USA
    Acta Orthop 84:571-8. 2013
    ..An algorithm was subsequently developed to convert these preferences into health state utilities that can be used to assess DC's impact on quality of life and the value of its treatments...
  14. pmc Mapping of the Insomnia Severity Index and other sleep measures to EuroQol EQ-5D health state utilities
    Ning Yan Gu
    Pharmerit North America, LLC, 4350 East West Highway, Suite 430, Bethesda, MD 20814, USA
    Health Qual Life Outcomes 9:119. 2011
    ..This study sought to map the Insomnia Severity Index (ISI) and symptom variables onto the EQ-5D...
  15. doi request reprint Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer
    John A Carter
    Pharmerit North America LLC, Bethesda, MD 20814, USA
    Expert Rev Pharmacoecon Outcomes Res 12:425-37. 2012
    ..Zoledronic acid (and denosumab in comparison with zoledronic acid) have been found to be cost effective and cost ineffective depending on the analytical perspective and model parameters...
  16. ncbi request reprint Chronic lymphocytic leukemia: economic burden and quality of life: literature review
    Jennifer M Stephens
    HERQuLES, Bethesda, Maryland, USA
    Am J Ther 12:460-6. 2005
    ..In summary, the impact of this disease on the health care budget of the different health care providers and payers as well as on the patient's QOL is substantially unknown, calling for appropriate economic and QOL studies...
  17. ncbi request reprint Needlestick injuries in the United States. Epidemiologic, economic, and quality of life issues
    Jennifer M Lee
    Abt Associates, Inc, Bethesda, Maryland, USA
    AAOHN J 53:117-33. 2005
    ..However, widespread use of safety devices might be more easily justified on economic grounds when the full clinical and economic benefits of these new technologies are considered, especially within the context of injury prevention...
  18. ncbi request reprint A cost-effectiveness evaluation of two continuous-combined hormone therapies for the management of moderate-to-severe vasomotor symptoms
    Marc F Botteman
    Abt Associates Inc, Bethesda, MD, USA Pfizer Inc, New York, NY, USA
    Menopause 11:343-55. 2004
    ..625 mg/day of conjugated estrogens plus 2.5 mg of medroxyprogesterone (0.625/2.5 CEE/MPA) compared with no therapy for the management of moderate-to-severe vasomotor symptoms...
  19. ncbi request reprint Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States
    Christopher E Bell
    Abt Associates Inc, Health Economic Research and Quality of Life Evaluation Services, Bethesda, Maryland, USA
    Clin Ther 25:2464-86. 2003
    ..The Intercept Blood System (IBS) for platelets has been developed to reduce pathogen transmission risks during transfusions...
  20. ncbi request reprint Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model
    Marc F Botteman
    Pharmerit North America LLC, Bethesda, Maryland 20814, USA
    CNS Drugs 21:319-34. 2007
    ..This analysis assessed, from a broad payer and societal perspective, the cost effectiveness of long-term treatment with eszopiclone (LUNESTA, Sepracor Inc., [Marlborough, MA, USA]) for chronic primary insomnia in adults in the US...
  21. doi request reprint Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United kingdom
    Avani D Joshi
    Health Economics, Pharmerit International, Bethesda, Maryland, USA
    Clin Ther 33:291-304.e8. 2011
    ..Zoledronic acid (ZOL) significantly reduces the risk of new skeletal-related events (SREs) in patients with non-small cell lung cancer (NSCLC) who have bone metastases...
  22. ncbi request reprint Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors
    Jennifer M Stephens
    Pharmerit North America LLC, 7272 Wisconsin Ave, Suite 300, Bethesda, MD 20814 4858, USA
    Expert Opin Pharmacother 8:1127-36. 2007
    ....
  23. ncbi request reprint Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature
    Jennifer M Stephens
    Pharmerit North America, LLC, 7272 Wisconsin Ave, Suite 300, Bethesda, Maryland 20814, USA
    J Manag Care Pharm 12:130-42. 2006
    ..To review the recent literature (January 2000-November 2005) regarding the impact of antidiabetic medications and glycemic control on the overall costs of care for patients with diabetes in U.S. managed care organizations (MCOs)...
  24. ncbi request reprint Economic burden of head and neck cancer. A literature review
    Jennifer M Lee
    Abt Associates Inc, Health Economic Research and Quality of Life Evaluation Services, Bethesda, MD, USA
    Eur J Health Econ 5:70-80. 2004
    ..Inclusion of economic components in clinical trials and the conduct of retrospective or prospective observational studies, such as patient registries, would yield important new information...
  25. ncbi request reprint Bladder cancer: epidemiology, diagnosis, and management
    Chris Leo Pashos
    Abt Associates Clinical Trials, Cambridge, Massachusetts, USA
    Cancer Pract 10:311-22. 2002
    ..The purpose of this article is to present an overview of the epidemiology diagnosis, and management of bladder cancer, with a focus on the early stage of this disease...
  26. ncbi request reprint Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States
    Joseph A Caprini
    Evanston Northwestern Healthcare, Evanston, IL, USA
    Value Health 6:59-74. 2003
    ..Estimates of the cost of long-term complications of a primary deep vein thrombosis (DVT), including the post-thrombotic syndrome (PTS) and recurrent venous thromboembolism (VTE), may be relevant for resource allocation decisions...
  27. ncbi request reprint Economic burden of acute myeloid leukemia: a literature review
    Alberto Redaelli
    Global Outcomes Research Oncology, Pharmacia Corporation, Via Robert Koch 1 2, 20152 Milan, Italy
    Cancer Treat Rev 30:237-47. 2004
    ..AML is the most common form of acute leukemia in adults, particularly in individuals over 60 years of age; AML also accounts for 15-20% of childhood leukemia...
  28. ncbi request reprint Cost-effectiveness model of long-acting risperidone in schizophrenia in the US
    Natalie C Edwards
    Health Services Consulting Corporation, Boxborough, Massachusetts, USA
    Pharmacoeconomics 23:299-314. 2005
    ..The availability of a long-acting injection (LAI) formulation of risperidone may increase adherence and improve clinical and economic outcomes for people with schizophrenia...
  29. ncbi request reprint Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis
    Kenneth W Purdy
    University of California Los Angeles UCLA Center for Vaccine Research, Research and Education Institute, Harbor UCLA Medical Center, Torrance, CA 90502 2502, USA
    Clin Infect Dis 39:20-8. 2004
    ..A recommendation for booster vaccinations every 10 years requires more information about duration of immunity, program costs, compliance, and nonmedical costs associated with pertussis...
  30. ncbi request reprint Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors
    Ashish V Joshi
    Novo Nordisk Inc, Princeton, NJ, USA
    Curr Med Res Opin 22:23-31. 2006
    ....
  31. ncbi request reprint Economic impact and quality-of-life burden of allergic rhinitis
    William F Schoenwetter
    Park Nicollet Clinic, St Louis Park, MN 55416, USA
    Curr Med Res Opin 20:305-17. 2004
    ..It was concluded that greater awareness of the total economic burden of allergic rhinitis should encourage appropriate intervention and ultimately ensure clinically favorable and cost-effective outcomes...
  32. ncbi request reprint Short- and long-term effects of acute myeloid leukemia on patient health-related quality of life
    Alberto Redaelli
    Global Outcomes Research Oncology, Pharmacia Corporation, Via Robert Koch 1 2, Milan 20152, Italy
    Cancer Treat Rev 30:103-17. 2004
    ..g., chemotherapy and bone marrow transplantation (BMT)) that are thought to significantly affect HRQL. Therefore, the goal of this study was to assess the HRQL impact on patients of AML and its treatments...
  33. ncbi request reprint Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus
    Joe W Ramsdell
    Division of General Internal Medicine and Geriatrics, University of California San Diego Medical Center, San Diego, CA, USA
    Pharmacoeconomics 21:819-37. 2003
    ..To assess the short-term direct medical costs and effectiveness associated with achieving recommended glycaemic goals using commonly prescribed first-line oral antihyperglycaemic medications in type 2 diabetes mellitus...
  34. ncbi request reprint Economic impacts attributable to the early clinical benefit of atorvastatin therapy--a US managed care perspective
    Robert J Straka
    University of Minnesota, Minneapolis, MN, USA
    Curr Med Res Opin 23:1517-29. 2007
    ..The present analysis modeled the clinical and economic consequences of initiating atorvastatin versus generic simvastatin in defined US managed care organization patient populations...